New Delhi, Jan 14 (IANS) New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report.
The report by GlobalData, a data and analytics company, showed that the growth will particularly be visible in eight major markets — US, France, Germany, Italy, Spain, UK, Japan, and China.
The report forecasted that the Alzheimer’s disease market in these countries to grow from $2.4 billion in 2023 to $19.3 billion by 2033 at a compound annual growth rate (CAGR) of 23.4 per cent.
This will be primarily driven by the entry of expensive disease-modifying therapies (DMTs) into the market, which will likely result in increased treatment rates as more options become available. An ageing global population leading to an increase in prevalent cases, and the launch of novel symptomatic therapies for the treatment of agitation and psychosis associated with Alzheimer’s disease will also contribute to the growth.
By 2033, DMTs are expected to dominate the global Alzheimer’s disease market, contributing 73.5 per cent of the market, with drugs targeting amyloid beta making up the majority of this, the report said.
Philippa Salter, Managing Neurology Analyst at GlobalData, said that Eisai/Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) will become the top-selling drugs for Alzheimer’s, and “will generate global sales of approximately $3.6 billion and $3.8 billion, respectively, by 2033”.
The report also noted barriers for these DMTs, which will limit their integration into clinical practice. Frequent IV administration and access to positron emission tomography (PET) and magnetic resonance imaging (MRI) scans are key economic and operational limiting factors for access to these drugs.
“In addition to logistical factors, these new DMTs are significantly more expensive than the current highly genericised symptomatic treatments used in the management of AD, providing a further access challenge in the form of reimbursement/payer restrictions,” Salter said
To counter these, drugmakers are probing alternative routes of administration. Several oral late-stage products in the pipeline can enable easier integration into clinical practice.
These include Anavex Life Sciences’ ANAVEX2-73 (blarcamesine), TauRx Therapeutics’ LMTX (hydromethylthionine mesylate), and Novo Nordisk’s NN-6535 (semaglutide).
The new DMTs are only considered moderately effective, so significant opportunity remains for more effective DMTs that do not just slow progression but also stop the disease, with prevention being the end goal.
Beyond DMTS, drugs that can effectively improve cognition in the late stages of the disease, as well as more effective options for secondary symptoms such as agitation and psychosis, also provide opportunities for developers.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
